Checkpoint Inhibitors: Drug Mechanism Design Pattern
Status: Phase 1 Complete -- Module + 5 Pilot Entries
1. Landscape: Which Diseases Are Treated by Checkpoint Inhibitors?
Diseases with checkpoint inhibitor treatments currently in dismech
| Disease | Drugs Referenced | Has target_mechanisms? |
Has Immune Evasion Pathophys Node? |
|---|---|---|---|
| MSI-High Colorectal Cancer | pembrolizumab, nivolumab, ipilimumab, dostarlimab | Yes | Yes ("PD-L1 Upregulation and Immune Evasion") |
| Clear Cell Renal Cell Carcinoma | nivolumab, pembrolizumab, ipilimumab | Yes | Yes ("Immune Evasion via PD-L1 and Immunosuppressive Microenvironment") |
| Hepatocellular Carcinoma | atezolizumab, durvalumab, tremelimumab | Yes | Yes ("Immune Evasion via PD-L1 and Immunosuppressive Microenvironment") |
| BRAF V600 Mutant Melanoma | pembrolizumab, nivolumab, ipilimumab | Yes | Yes ("Immune Evasion via PD-L1 Upregulation") |
| NRAS Mutant Melanoma | checkpoint inhibitors (narrative) | No | Partial |
| KIT Mutant Melanoma | checkpoint inhibitors (narrative) | No | Partial |
| Cutaneous Squamous Cell Carcinoma | cemiplimab | No | Partial |
| Non-Small Cell Lung Cancer | checkpoint inhibitors (narrative) | No | Partial |
| Small Cell Lung Cancer | checkpoint inhibitors (narrative) | No | Partial |
| KRAS G12C Mutant NSCLC | checkpoint inhibitors (narrative) | No | Partial |
| Cervical Cancer | pembrolizumab | No | Partial |
| Triple-Negative Breast Cancer | atezolizumab/pembrolizumab (narrative) | No | Yes (immunomodulatory subtype) |
| Nasopharyngeal Carcinoma | PD-1 inhibitors | Yes | Yes ("Immune Evasion") |
| HPV-Positive Head and Neck Cancer | checkpoint inhibitors (narrative) | No | Yes ("Immune Evasion") |
| Merkel Cell Carcinoma | avelumab (narrative) | No | Partial |
| MSI-High Endometrial Cancer | checkpoint inhibitors (narrative) | No | Partial |
| FGFR-Altered Cholangiocarcinoma | durvalumab | No | No |
| IDH-Mutant Cholangiocarcinoma | durvalumab | No | No |
| Malignant Mesothelioma | checkpoint inhibitors (narrative) | No | Partial |
| Basal Cell Carcinoma | cemiplimab (narrative) | No | Partial |
| EBV-Associated Gastric Cancer | checkpoint inhibitors (narrative) | No | Partial |
| Osteosarcoma | checkpoint inhibitors (narrative) | No | Yes ("Tumor Immune Microenvironment Remodeling") |
| Uveal Melanoma | checkpoint inhibitors (noted as poor response) | No | Noted as "immunologically cold" |
Diseases where checkpoint molecules appear in pathophysiology (not treatment)
| Disease | Context |
|---|---|
| Hepatitis B | T cell exhaustion with PD-1, CTLA-4, TIM-3 upregulation |
| Addison's Disease | CTLA4 as autoimmune susceptibility gene |
| Diabetes Mellitus | Checkpoint inhibitor exposure as disease trigger |
| Type 1 Diabetes | Immune checkpoint pathway involvement |
| Autoimmune diseases (multiple) | CTLA-4/PD-1 polymorphisms in autoimmune susceptibility |
2. Current Representation Gaps
Treatment side
- No
target_mechanismslinks: Not a single checkpoint inhibitor treatment usestarget_mechanismsto connect back to the immune evasion pathophysiology node it addresses. This is the core structural gap. - All mapped to generic
NCIT:C15986(Pharmacotherapy) orNCIT:C15262(Immunotherapy): No specific NCIT term for "immune checkpoint inhibitor therapy" exists. The best available terms areNCIT:C15986(Pharmacotherapy) andNCIT:C15262(Immunotherapy); pair with atherapeutic_agent. - No shared mechanism-of-action concept: Each disease independently describes what PD-1/PD-L1 blockade does in its description text. There's no reusable structure.
Pathophysiology side
- Inconsistent immune evasion modeling: Some cancers have explicit "Immune Evasion" or "PD-L1 Upregulation" pathophysiology nodes; many only mention checkpoint molecules in narrative text.
- No shared immune evasion module: Unlike
fibrotic_response, there is noimmune_evasionmodule that defines the conserved pattern of: neoantigen presentation → T cell infiltration → adaptive PD-L1 upregulation → T cell exhaustion → immune escape. - Cell type and GO term inconsistency: When immune cells are annotated, the terms vary (CL:0000625 for CD8+ T cells in some, CL:0000084 for generic T cells in others).
The disconnect
The treatment and pathophysiology sections describe the same biological process from opposite directions but are not structurally linked: - Pathophysiology says: "Tumor upregulates PD-L1 → suppresses T cells → immune evasion" - Treatment says: "Anti-PD-1 blocks this interaction → restores T cell function"
But there's no target_mechanisms edge connecting the treatment to the pathophysiology node.
3. Proposal: Drug Mechanism Classes as Design Patterns
Concept
Just as kb/modules/fibrotic_response.yaml defines a conserved pathological process that multiple diseases conforms_to, we should create mechanism-of-action modules that capture conserved drug response patterns. These would serve as design patterns for how treatments connect to pathophysiology.
Proposed Module: immune_checkpoint_blockade
kb/modules/immune_checkpoint_blockade.yaml
This module would define the conserved pattern:
Pathophysiology side (the disease process being targeted):
1. Neoantigen Generation → high TMB produces immunogenic peptides
2. Anti-Tumor Immune Response → CD8+ T cells recognize and infiltrate tumor
3. Adaptive Immune Resistance → tumor upregulates PD-L1/PD-L2 in response to IFN-gamma
4. T Cell Exhaustion and Immune Escape → chronic checkpoint engagement → dysfunctional T cells → tumor evades destruction
Treatment side (the therapeutic intervention):
Anti-PD-1/PD-L1 therapy:
target_mechanisms:
- target: "Adaptive Immune Resistance"
treatment_effect: INHIBITS
- target: "T Cell Exhaustion"
treatment_effect: INHIBITS
→ downstream effect: restores "Anti-Tumor Immune Response"
Anti-CTLA-4 therapy:
target_mechanisms:
- target: "T Cell Exhaustion" (priming phase)
treatment_effect: INHIBITS
→ downstream effect: expands T cell repertoire
How diseases would conform
# In kb/disorders/MSI_High_Colorectal_Cancer.yaml
pathophysiology:
- name: Neoantigen-Driven Immune Response
conforms_to: "immune_checkpoint_blockade#Anti-Tumor Immune Response"
# organ-specific: high TMB from dMMR
...
- name: PD-L1 Upregulation and Immune Evasion
conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
...
treatments:
- name: Pembrolizumab
...
target_mechanisms:
- target: PD-L1 Upregulation and Immune Evasion
treatment_effect: INHIBITS
description: Anti-PD-1 blocks PD-1/PD-L1 interaction, restoring T cell cytotoxicity
Why this matters
-
Consistency: Every cancer with checkpoint inhibitor treatment would model immune evasion the same way, with organ-specific substitutions (just like fibrotic response uses organ-specific fibroblasts).
-
Predictive power: If a cancer has a pathophysiology node conforming to the immune evasion pattern, it suggests checkpoint inhibitor sensitivity. Conversely, cancers like Uveal Melanoma that lack the pattern ("immunologically cold") explain treatment resistance.
-
Completeness checking: If a disease has a checkpoint inhibitor treatment but no immune evasion pathophysiology node (e.g., FGFR-Altered Cholangiocarcinoma), that's a curation gap.
-
Bidirectional linking:
target_mechanismsformally connects treatment → pathophysiology, closing the current structural gap.
Additional mechanism-of-action modules to consider
| Module | Diseases | Pattern |
|---|---|---|
immune_checkpoint_blockade |
~23 cancers | Neoantigen → immune infiltration → adaptive resistance → checkpoint blockade restores immunity |
kinase_inhibition |
ALK NSCLC, BRAF Melanoma, FGFR cancers, CML | Constitutive kinase activation → oncogenic signaling → TKI blocks kinase → pathway shutdown |
antibody_dependent_cellular_cytotoxicity |
HER2+ cancers, lymphomas | Surface antigen overexpression → antibody binding → Fc-mediated immune recruitment |
angiogenesis_inhibition |
RCC, HCC, CRC | VEGF overproduction → neovascularization → anti-VEGF starves tumor |
differentiation_therapy |
APL (ATRA/ATO) | Differentiation block → pharmacologic override → terminal differentiation |
synthetic_lethality |
BRCA-mutant cancers (PARP inhibitors) | DNA repair deficiency → PARP inhibition → unrepaired damage → cell death |
cdk_inhibition |
HR+ breast cancer, liposarcoma | Cyclin D-CDK4/6 overactivation → Rb phosphorylation → CDK4/6i arrests G1/S → senescence |
4. Implementation Plan
Phase 1 (DONE)
- [x] Verify NCIT terms -- no specific "immune checkpoint inhibitor therapy" term in NCIT;
NCIT:C15986(Pharmacotherapy) andNCIT:C15262(Immunotherapy) are the best available - [x] Create
kb/modules/immune_checkpoint_blockade.yamlwith 4-node conserved pattern: - Neoantigen Generation (GO:0019882)
- Anti-Tumor T Cell Response (CL:0000625, GO:0042110, GO:0001913)
- Adaptive Immune Resistance (GO:0002710) -- primary conforms_to target
- T Cell Exhaustion and Immune Escape (CL:0011025, GO:0160083)
- [x] Update 5 pilot cancer entries with
conforms_toandtarget_mechanisms: - MSI-High Colorectal Cancer -- 3 ICI treatments linked, 2 pathophys nodes with conforms_to
- Clear Cell Renal Cell Carcinoma -- new immune evasion node added, ICI treatment linked
- Hepatocellular Carcinoma -- new immune evasion node added, 2 ICI treatments linked (atezo+bev also targets angiogenesis)
- BRAF V600 Mutant Melanoma -- new immune evasion node added, ICI treatment linked
- Nasopharyngeal Carcinoma -- existing "Immune Evasion" node gets conforms_to, immunotherapy treatment linked
- [x] Standardize: all immune evasion nodes use CL:0000625 (CD8+ T cell) and GO:0002710 (negative regulation of T cell mediated immunity)
Phase 2 (TODO)
- [ ] Extend to remaining ~18 cancers with checkpoint inhibitor treatments
- [ ] Add specific therapeutic_agent annotations to entries that currently lack them (NCIT/CHEBI IDs)
- [ ] Create additional mechanism modules:
kinase_inhibition,angiogenesis_inhibition,synthetic_lethality - [ ] Document the "drug mechanism module" pattern in CLAUDE.md
- [ ] Consider schema evolution:
mechanism_classslot on Treatment,conforms_toon Treatment - [ ] Model irAE (immune-related adverse events) as cross-disease comorbidity pattern
- [ ] Add CDK4/6 inhibitor mechanism module (from second analysis)
5. Key Questions
- Schema evolution: Should
conforms_toon Treatment (not just pathophysiology) point to a mechanism module? Currently only pathophysiology nodes conform to modules. - Granularity: Should anti-PD-1 and anti-CTLA-4 be separate sub-patterns within the module, or one unified checkpoint blockade pattern?
- Resistance modeling: How to represent acquired resistance (e.g., loss of B2M, JAK1/2 mutations) that breaks the checkpoint blockade pattern?
- Adverse events as pattern: Checkpoint inhibitor-induced autoimmunity (irAEs) is itself a conserved pattern -- model as a separate module or within the same one?
- Biomarker integration: PD-L1 expression, TMB, and MSI status predict checkpoint response. Should the module include biomarker nodes?
6. Observations on Autoimmune Mirror
Checkpoint inhibitors work by removing immune brakes. This is the mirror image of autoimmune diseases where checkpoint pathways are insufficient. The same module could potentially be used bidirectionally: - Cancer: Checkpoint engagement = disease mechanism → blockade = treatment - Autoimmune: Checkpoint insufficiency = disease mechanism → checkpoint agonism = (theoretical) treatment - irAEs: Checkpoint blockade (cancer treatment) → autoimmune pathology (adverse event)
This triangulation supports the "design pattern" framing -- the same biological pattern manifests differently depending on which direction it's perturbed.